Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03219619
Other study ID # KY20170517-3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2018
Est. completion date July 20, 2018

Study information

Verified date October 2019
Source Fourth Military Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Examination of major duodenal papilla (MDP) using a side-viewing duodenoscope is a golden standard. However, side-viewing duodenoscope is not available in some endoscopic centers. Cap-assisted esophagogastroduodenoscopy (Ca-EGD) using a transparent cap fitted to the tip of the scope has emerged as an alternative method for the observation of MDP. A recent study showed that complete examination of MDP could be achieved in 97% of patients. The investigators hypothesize that Ca-EGD is non-inferior to duodenoscope for the observation of MDP.


Description:

Interim analyses were planned to be performed by the data and safety monitoring board after data collection has been completed for 50% of the enrollment.


Recruitment information / eligibility

Status Completed
Enrollment 171
Est. completion date July 20, 2018
Est. primary completion date July 20, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Age > 18 years and < 70 years

- Patients with native MDP who underwent ERCP

Exclusion Criteria:

- Prior surgery in upper GI tract

- Prior history of endoscopic sphincterotomy

- Prior history of MDP treatment

- Known or suspected obstruction of upper GI tract

- Patients in poor condition who may not be suitable for Ca-EGD or duodenoscope

- Pregnancy or lactic women

- Inability to give informed consent

Study Design


Related Conditions & MeSH terms

  • Observation of Major Duodenal Papilla (MDP)

Intervention

Device:
Cap-EGD
Undergoing cap-assisted endoscopy
Duo
Undergoing side-viewing duodenoscope

Locations

Country Name City State
China Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University Chongqing
China Endoscopic center, Xijing Hospital of Digestive Diseases Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Fourth Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of complete examination of MDP Complete examination is defined by visualization of both proximal and distal ends with orifice of papilla 5 minutes after intubation of the esophagus
Secondary Endoscopic findings in descending duodenum All pathological findings which are seen in descending duodenum should be reported (e.g. ampullary adenoma, peripapillary diverticulum, ampullary carcinoma, inflammatory change of papilla, etc) 5 minutes after intubation of the esophagus
Secondary Overall endoscopic findings All pathological findings which are seen during the examination should be reported (e.g. reflux esophagitis, gastric cancer, gastric ulcer, duodenal ulcer, etc) 5 minutes after intubation of the esophagus
Secondary MDP examination time The times taken for the examination of the MDP (after passing the pylorus until examination of MDP) 5 minutes after intubation of the esophagus
Secondary MDP examination score Score 3 when proximal end, distal end and orifice were visualized; Score 2 when either proximal or distal end with orifice were visualized; Score 1 when either proximal or distal end without orifice was visualized; Score 0 when the MDP could not be localized 5 minutes after intubation of the esophagus